Metagenomi to Present at Upcoming Scientific Meetings
- Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024
- Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8 & 9, 2024
EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: a late breaking oral presentation at The World Federation of Hemophilia (WFH) World Congress, taking place April 21 – 24, 2024 in Madrid, Spain and two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.
WFH 2024 World Congress
Madrid, Spain
April 21-24, 2024
Oral Presentation Title: Metagenomi:
Potentially Curative Gene Editing Approach for Hemophilia A
Session: Late breaking session: New tech
Location: N103+N104
Date / time: Tuesday, April 23, 2024, 16:00 – 17:00 CEST
ASGCT 2024 Annual Meeting
Baltimore, MD
May 7-9, 2024
Poster Title: Novel CRISPR Effectors and Reverse Transcriptases Discovered from Metagenomics Enable Extensive Remodeling of the Human Genome
Abstract Number: 1209
Location: Exhibit Hall
Date / time: Thursday, May 9, 2024, 12:00 p.m. ET
Lesen Sie auch
Poster Title: Novel and Efficient Base Editors Engineered to Comprehensively Target the Human Genome
Abstract Number: 684
Location: Exhibit Hall
Date / time: Wednesday, May 8, 2024, 12:00 p.m. ET
All presentations will be made available on the "News & Events," page in the Investors section of the Company's website at https://ir.metagenomi.co/news-events/events.
About Metagenomi
Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived toolbox. Metagenomi is harnessing the power of metagenomics, the study of genetic material recovered from the natural environment, to unlock four billion years of microbial evolution to discover and develop a suite of novel editing tools capable of correcting any type of genetic mutation found anywhere in the genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases). Metagenomi believes its diverse and modular toolbox positions the company to access the entire genome and select the optimal tool to unlock the full potential of genome editing for patients. For more information, please visit https://metagenomi.co.